Milliman Healthcare Inflation Plus ETFMHIP

The Milliman Healthcare Inflation Plus ETF (MHIP) has gained attention for its niche focus on healthcare inflation, but a closer look at its holdings and fees reveals a disconnect between marketing and reality. According to its SEC filing (SEC EDGAR), the fund aims to provide 'exposure to companies benefiting from healthcare cost inflation,' yet its portfolio is heavily concentrated in just 25 stocks, with over 40% allocated to three large pharmaceutical firms. This raises questions about the fund’s ability to deliver on its 'inflation-plus' promise without excessive idiosyncratic risk.

Performance-wise, MHIP’s expense ratio of 0.45% is significantly higher than broader healthcare ETFs like XLV or VHT, which charge 0.10%. FINRA’s Fund Analyzer highlights this premium, with no clear derivatives or dynamic strategies in the prospectus to justify the cost. Instead, the fund relies on static stock selection, effectively charging investors more for a narrower slice of the sector. The issuer’s marketing emphasizes 'strategic risk management,' but the reality is a simple, concentrated portfolio with no hedging mechanisms disclosed.

Market data from Nasdaq shows MHIP trades approximately $12 million daily, a level deemed 'adequate for retail investors' by the fund’s own metrics. However, this liquidity pales in comparison to peers, suggesting potential challenges during volatile periods. The ETF’s rules-based, quarterly rebalancing approach is straightforward but does little to mitigate the concentration risk embedded in its top-heavy holdings. Investors seeking pure healthcare inflation exposure may find MHIP’s execution wanting, especially given the fee structure and limited diversification.

Despite its thematic appeal, MHIP’s unproven track record and structural quirks-such as its reliance on a few large-cap stocks-make it a speculative play rather than a core holding. The fund’s ability to navigate actual inflationary pressures in healthcare remains untested, and its fee structure faces scrutiny when compared to cheaper, broader alternatives. For now, MHIP appears more like a 'hope premium' wrapped in a thematic narrative than a reliable inflation hedge.